Extracorporeal Membrane Oxygenation in Pregnant Women With COVID-19

ASAIO J. 2022 Apr 1;68(4):471-477. doi: 10.1097/MAT.0000000000001646.

Abstract

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and lung involvement is common. Patients with COVID-19 may progress to acute respiratory distress syndrome (ARDS) for which they may require mechanical ventilation. When conventional ventilation strategies are unable to achieve the desired oxygenation and gas exchange, extracorporeal membrane oxygenation (ECMO) might be an option in selected patients. The literature on the use of ECMO in peripartum women with COVID-19 is limited. We present a series of ten cases involving pregnant and recently pregnant women who rapidly developed ARDS after the onset of COVID-19 for which they received ECMO. Nine of the 10 patients survived intensive care unit discharge after a gradual recovery of their pulmonary function and weaning from mechanical ventilation and ECMO. In addition, 9 out of the 10 delivered neonates survived neonatal intensive care unit discharge.

MeSH terms

  • COVID-19* / therapy
  • Extracorporeal Membrane Oxygenation* / adverse effects
  • Female
  • Humans
  • Infant, Newborn
  • Pregnancy
  • Pregnant Women
  • Respiratory Distress Syndrome* / therapy
  • SARS-CoV-2